Home LiteratureArticle Details
PMID: 22258607 Published · epublish English Journal Article Research Support, Non-U.S. Gov't Review

The DNA damage response and cancer therapy.

Nature ·Vol. 481 ·No. 7381 ·2012-01-18 ·Pages 287-94

Lord CJ, Ashworth A

Abstract

Genomic instability is one of the most pervasive characteristics of tumour cells and is probably the combined effect of DNA damage, tumour-specific DNA repair defects, and a failure to stop or stall the cell cycle before the damaged DNA is passed on to daughter cells. Although these processes drive genomic instability and ultimately the disease process, they also provide therapeutic opportunities. A better understanding of the cellular response to DNA damage will not only inform our knowledge of cancer development but also help to refine the classification as well as the treatment of the disease.

MeSH Terms
DNA Damage/drug effects DNA Repair/drug effects Genomic Instability/drug effects Humans Molecular Targeted Therapy Neoplasms/genetics,pathology,therapy Neoplastic Stem Cells/drug effects,pathology Poly(ADP-ribose) Polymerase Inhibitors Poly(ADP-ribose) Polymerases/metabolism Tumor Microenvironment/drug effects
Chemicals
Poly(ADP-ribose) Polymerase Inhibitors Poly(ADP-ribose) Polymerases
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Lord Christopher J
The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK. chris.lord@icr.ac.uk
Ashworth Alan
References (72)
72 references, click to expand
  1. Integrating genetic approaches into the discovery of anticancer drugs.
    Science. 1997 Nov 7;278(5340):1064-8 PMID: 9353181
  2. Hallmarks of cancer: the next generation.
    Cell. 2011 Mar 4;144(5):646-74 PMID: 21376230
  3. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.
    Cancer Cell. 2011 May 17;19(5):664-78 PMID: 21575865
  4. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
    Nature. 2005 Apr 14;434(7035):917-21 PMID: 15829967
  5. Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanfgaster.
    Genetics. 1968 May;59(1):37-44 PMID: 5683639
  6. Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity.
    Nat Rev Genet. 2009 Nov;10(11):756-68 PMID: 19809470
  7. Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture.
    Biochem Pharmacol. 1995 Aug 25;50(5):705-14 PMID: 7669074
  8. Making the best of PARP inhibitors in ovarian cancer.
    Nat Rev Clin Oncol. 2010 Sep;7(9):508-19 PMID: 20700108
  9. NHEJ and its backup pathways in chromosomal translocations.
    Nat Struct Mol Biol. 2010 Apr;17(4):393-5 PMID: 20368722
  10. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.
    Cancer Res. 2009 Aug 15;69(16):6381-6 PMID: 19654294
  11. MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
    Nat Rev Neurol. 2010 Jan;6(1):39-51 PMID: 19997073
  12. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.
    Nature. 2006 Dec 7;444(7120):756-60 PMID: 17051156
  13. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors.
    Mol Cell. 2011 Jan 21;41(2):210-20 PMID: 21195000
  14. PARP inhibition: PARP1 and beyond.
    Nat Rev Cancer. 2010 Apr;10(4):293-301 PMID: 20200537
  15. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis.
    Nat Rev Mol Cell Biol. 2010 Mar;11(3):196-207 PMID: 20177395
  16. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.
    Chem Biol. 2010 May 28;17(5):421-33 PMID: 20534341
  17. Complex landscapes of somatic rearrangement in human breast cancer genomes.
    Nature. 2009 Dec 24;462(7276):1005-10 PMID: 20033038
  18. 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.
    Cancer Res. 2010 Aug 1;70(15):6268-76 PMID: 20631063
  19. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.
    J Clin Oncol. 2011 Aug 1;29(22):3008-15 PMID: 21709188
  20. Correlation of DNA adduct levels in human lung with cigarette smoking.
    Nature. 1988 Dec 22-29;336(6201):790-2 PMID: 3205307
  21. The combined status of ATM and p53 link tumor development with therapeutic response.
    Genes Dev. 2009 Aug 15;23(16):1895-909 PMID: 19608766
  22. Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC.
    Clin Cancer Res. 2011 Sep 1;17(17):5562-72 PMID: 21750204
  23. Integrated genomic analyses of ovarian carcinoma.
    Nature. 2011 Jun 29;474(7353):609-15 PMID: 21720365
  24. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.
    Cancer Res. 2006 Aug 15;66(16):8109-15 PMID: 16912188
  25. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
    N Engl J Med. 2009 Jul 9;361(2):123-34 PMID: 19553641
  26. Exploring the genomes of cancer cells: progress and promise.
    Science. 2011 Mar 25;331(6024):1553-8 PMID: 21436442
  27. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.
    Br J Cancer. 2011 Jul 26;105(3):372-81 PMID: 21730979
  28. Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers.
    Cancer Discov. 2011 Jun;1(1):29-34 PMID: 22586318
  29. Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications.
    Genes Dev. 2011 Mar 1;25(5):409-33 PMID: 21363960
  30. Identification of human brain tumour initiating cells.
    Nature. 2004 Nov 18;432(7015):396-401 PMID: 15549107
  31. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.
    Nature. 2009 Apr 9;458(7239):732-6 PMID: 19360080
  32. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
    Nature. 2005 Apr 14;434(7035):913-7 PMID: 15829966
  33. Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura.
    Genetics. 1946 May;31:269-90 PMID: 20985721
  34. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
    Clin Cancer Res. 2012 Jan 15;18(2):510-23 PMID: 22128301
  35. PARP inhibitor development for systemic cancer targeting.
    Anticancer Agents Med Chem. 2007 Sep;7(5):515-23 PMID: 17896912
  36. Role for the mammalian Swi5-Sfr1 complex in DNA strand break repair through homologous recombination.
    PLoS Genet. 2010 Oct 14;6(10):e1001160 PMID: 20976249
  37. Massive genomic rearrangement acquired in a single catastrophic event during cancer development.
    Cell. 2011 Jan 7;144(1):27-40 PMID: 21215367
  38. Base-excision repair of oxidative DNA damage.
    Nature. 2007 Jun 21;447(7147):941-50 PMID: 17581577
  39. DNA damage, aging, and cancer.
    N Engl J Med. 2009 Oct 8;361(15):1475-85 PMID: 19812404
  40. Mutagenesis and carcinogenesis caused by the oxidation of nucleic acids.
    Biol Chem. 2006 Apr;387(4):373-9 PMID: 16606334
  41. Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris.
    J Cell Sci. 2008 Jan;121 Suppl 1:1-84 PMID: 18089652
  42. Synthetic lethality: a framework for the development of wiser cancer therapeutics.
    Genome Med. 2009 Oct 27;1(10):99 PMID: 19863774
  43. Pancreatic stellate cells radioprotect pancreatic cancer cells through β1-integrin signaling.
    Cancer Res. 2011 May 15;71(10):3453-8 PMID: 21558392
  44. Determinants and dynamics of genome accessibility.
    Nat Rev Genet. 2011 Jul 12;12(8):554-64 PMID: 21747402
  45. Dealing with DNA damage: relationships between checkpoint and repair pathways.
    Mutat Res. 2010 Apr-Jun;704(1-3):2-11 PMID: 20006736
  46. Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer.
    PLoS One. 2011;6(7):e21639 PMID: 21750719
  47. Resistance to therapy caused by intragenic deletion in BRCA2.
    Nature. 2008 Feb 28;451(7182):1111-5 PMID: 18264088
  48. Association of reactive oxygen species levels and radioresistance in cancer stem cells.
    Nature. 2009 Apr 9;458(7239):780-3 PMID: 19194462
  49. An oncogene-induced DNA damage model for cancer development.
    Science. 2008 Mar 7;319(5868):1352-5 PMID: 18323444
  50. Immortal strands? Give me a break.
    Cell. 2007 Jun 29;129(7):1244-7 PMID: 17604711
  51. The USP1/UAF1 complex promotes double-strand break repair through homologous recombination.
    Mol Cell Biol. 2011 Jun;31(12):2462-9 PMID: 21482670
  52. Selective targeting of radiation-resistant tumor-initiating cells.
    Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3522-7 PMID: 20133717
  53. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.
    Cancer Res. 2008 Apr 15;68(8):2581-6 PMID: 18413725
  54. Chromosome catastrophes involve replication mechanisms generating complex genomic rearrangements.
    Cell. 2011 Sep 16;146(6):889-903 PMID: 21925314
  55. The DNA damage response: making it safe to play with knives.
    Mol Cell. 2010 Oct 22;40(2):179-204 PMID: 20965415
  56. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
    Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84 PMID: 18971340
  57. Genome maintenance mechanisms for preventing cancer.
    Nature. 2001 May 17;411(6835):366-74 PMID: 11357144
  58. The multifaceted mismatch-repair system.
    Nat Rev Mol Cell Biol. 2006 May;7(5):335-46 PMID: 16612326
  59. Hallmarks of 'BRCAness' in sporadic cancers.
    Nat Rev Cancer. 2004 Oct;4(10):814-9 PMID: 15510162
  60. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.
    Nat Med. 2011 Jun 26;17(7):875-82 PMID: 21706030
  61. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints.
    Nature. 2006 Nov 30;444(7119):633-7 PMID: 17136093
  62. Telomeres and telomerase in cancer.
    Carcinogenesis. 2010 Jan;31(1):9-18 PMID: 19887512
  63. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
    Nature. 2008 Feb 28;451(7182):1116-20 PMID: 18264087
  64. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.
    EMBO Mol Med. 2009 Sep;1(6-7):315-22 PMID: 20049735
  65. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer.
    Clin Cancer Res. 2010 Dec 15;16(24):6159-68 PMID: 20802015
  66. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2.
    EMBO Mol Med. 2009 Sep;1(6-7):323-37 PMID: 20049736
  67. Targeted therapy for cancer using PARP inhibitors.
    Curr Opin Pharmacol. 2008 Aug;8(4):363-9 PMID: 18644251
  68. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.
    Nat Struct Mol Biol. 2010 Jun;17(6):688-95 PMID: 20453858
  69. Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks.
    Nature. 2009 Dec 17;462(7275):935-9 PMID: 20016603
  70. Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers.
    Cancer Res. 2011 Mar 1;71(5):1836-48 PMID: 21242281
  71. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1.
    Cancer Cell. 2010 Mar 16;17(3):235-48 PMID: 20227038
  72. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks.
    Cell. 2010 Apr 16;141(2):243-54 PMID: 20362325
Article Info
Journal
Nature
Abbr.
Nature
ISSN
1476-4687
DOI
10.1038/nature10760
Email
chris.lord@icr.ac.uk
Published
2012-01-18
Epub
2012-00-18
Pages
287-94
Language
English
Region
England
NLM ID
0410462
Subset
IM
Grants
Breast Cancer Now · BREAST CANCER NOW RESEARCH CENTRE · United Kingdom
Wellcome Trust · United Kingdom
Cancer Research UK · United Kingdom
External Links
PubMed source DOI: 10.1038/nature10760 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2